欧盟上市药品（最近更新）
按更新时间最近更新
| 药品名称 | 活性成分 | 商品名 | 生产企业 | 审评状态 | 批准日期 | 更新日期 | 产品编号 | 治疗领域 | 适应症 |
|---|---|---|---|---|---|---|---|---|---|
| angiotensin II | Angiotensin II acetate | Giapreza | Paion Pharma GmbH | Authorised | 2019-08-23 | 2026-10-09 | EMEA/H/C/004930 | Hypotension、Shock | Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. |
| ranibizumab | ranibizumab | Lucentis | Novartis Europharm Limited | Authorised | 2007-01-22 | 2026-10-08 | EMEA/H/C/000715 | Wet Macular Degeneration、Macular Edema、Diabetes Complications、Myopia, Degenerative、Choroidal Neovascularization | Lucentis is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to choroidal neovascularisation (CNV)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) |
| mecasermin | Mecasermin | Increlex | Esteve Pharmaceuticals, S.A. | Authorised | 2007-08-02 | 2026-10-08 | EMEA/H/C/000704 | Laron Syndrome | For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD).Severe primary IGFD is defined by:height standard deviation score ? -3.0 and;basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and;growth hormone (GH) sufficiency;exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signalling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test. |
| tepotinib | Tepotinib hydrochloride monohydrate | Tepmetko | Merck Europe B.V. | Authorised | 2022-02-16 | 2026-10-08 | EMEA/H/C/005524 | Carcinoma, Non-Small-Cell Lung | Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
| tirzepatide | Tirzepatide | Mounjaro | Eli Lilly Nederland B.V. | Authorised | 2022-09-15 | 2026-10-08 | EMEA/H/C/005620 | Diabetes Mellitus, Type 2、Obesity、Overweight | Type 2 diabetes mellitusMounjaro is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.Weight managementMounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of≥ 30 kg/m2(obesity) or≥ 27 kg/m2 to < 30 kg/m2(overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).For trial results with respect to obstructive sleep apnoea (OSA) and heart failure with preserved ejection fraction (HFpEF), see section 5.1. |
| serplulimab | Serplulimab | Hetronifly | Accord Healthcare S.L.U. | Authorised | 2025-02-03 | 2026-10-08 | EMEA/H/C/006170 | Small Cell Lung Carcinoma、Carcinoma, Non-Small-Cell Lung、Esophageal Squamous Cell Carcinoma | Small cell lung cancer (SCLC)Hetronifly in combination with carboplatin and etoposide is indicated for the first‑line treatment of adult patients with extensive‑stage small cell lung cancer (ES‑SCLC).Non-small cell lung carcinoma (NSCLC)Hetronifly in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult non-squamous NSCLC patients with no EGFR, ALK or ROS1 positive mutations and who have:locally advanced NSCLC who are not candidates for surgery or radiotherapy, ormetastatic NSCLC.Oesophageal squamous cell carcinoma (OSCC)Hetronifly in combination with fluoropyrimidine- and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma whose tumours express PD-L1 with a CPS ≥ 5. |
| ritonavir | ritonavir | Ritonavir Viatris (previously Ritonavir Mylan) | Viatris Limited | Authorised | 2017-11-09 | 2026-10-07 | EMEA/H/C/004549 | HIV Infections | Ritonavir is indicated as a pharmacokinetic enhancer of co-administered protease inhibitors as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected patients (adults and children of 2 years of age and older). |
| ibrutinib | Ibrutinib | Imbruvica | Janssen-Cilag International NV | Authorised | 2014-10-21 | 2026-10-07 | EMEA/H/C/003791 | Lymphoma, Mantle-Cell、Leukemia, Lymphocytic, Chronic, B-Cell | Imbruvica in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with R-DHAP (or R-DHAOx) without Imbruvica, followed by Imbruvica monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT).Imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory MCL.Imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Imbruvica as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Imbruvica as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM. |
| abrocitinib | Abrocitinib | Cibinqo | Pfizer Europe MA EEIG | Authorised | 2021-12-09 | 2026-10-07 | EMEA/H/C/005452 | Dermatitis, Atopic | Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. |
| mosunetuzumab | mosunetuzumab | Lunsumio | Roche Registration GmbH | Authorised | 2022-06-03 | 2026-10-07 | EMEA/H/C/005680 | Lymphoma, Follicular | Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. |
上一页 第 3 / 3 页 下一页